midazolam has been researched along with rifampin in 93 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.08) | 18.7374 |
| 1990's | 6 (6.45) | 18.2507 |
| 2000's | 22 (23.66) | 29.6817 |
| 2010's | 48 (51.61) | 24.3611 |
| 2020's | 16 (17.20) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, WT; Schuetz, EG; Schuetz, JD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barra, Y; Cano, JP; Covo, J; Crevat-Pisano, P; Dragna, S; Fabre, G | 1 |
| Backman, JT; Neuvonen, PJ; Olkkola, KT | 1 |
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Olkkola, KT | 1 |
| De Winne, AJ; Desager, JP; Eeckhoudt, SL; Horsmans, Y; Verbeeck, RK | 1 |
| de Sousa, G; Dostert, P; Gugenheim, J; Ings, R; Rahmani, R; Reinach, B | 1 |
| Hansen, LK; Hosagrahara, VP; Remmel, RP | 1 |
| Beilman, GJ; Hansen, LK; Hosagrahara, VP; Remmel, RP | 1 |
| Desager, JP; Eeckhoudt, SL; Horsmans, Y; Leclercq, I; Robert, AR; Verbeeck, RK | 1 |
| Bigler, L; Follath, F; Ha, HR; Kozlik, P; Stieger, B | 1 |
| Kharasch, ED; Phimmasone, S | 1 |
| Akiyama, TE; Cheung, C; Elizondo, G; Feigenbaum, L; Gonzalez, FJ; Granvil, CP; Krausz, KW; Yu, AM | 1 |
| Ambrosius, WT; Bruce, MA; Gorski, JC; Haehner-Daniels, B; Hall, SD; Hamman, MA; Vannaprasaht, S | 1 |
| Bhat, K; Floyd, MD; George, AL; Gervasini, G; Kim, RB; Masica, AL; Mayo, G; Wilkinson, GR | 1 |
| Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Kim, JR; Lim, HS; Liu, KH; Oh, DS; Shin, JG; Shin, SG; Yi, SY; Yu, KS | 1 |
| Adams, M; Ahdieh, H; Gammaitoni, AR; Pieniaszek, HJ | 1 |
| Booker, BM; Brazeau, D; Cloen, D; Frerichs, V; Frye, RF; Haas, CE; Kufel, T; Zaranek, C | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Breen, P; Carrier, DJ; Cheboyina, S; Gentry, WB; Gurley, B; Hubbard, MA; Thaden, J; Tong, Y; Williams, DK | 1 |
| Carr, B; Kuo, Y; Li, C; Lin, JH; Lu, B; Prueksaritanont, T; Qiu, Y; Richards, K; Strong-Basalyga, K; Tang, C | 1 |
| Lin, JH | 1 |
| Gonzalez, FJ; Guo, GL; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Gentry, WB; Gurley, BJ; Hartsfield, F; Hubbard, MA; Swain, A; Thaden, J; Tong, Y; Williams, DK | 1 |
| Ben-Ari, A; Boutboul, E; Gershkovich, P; Gotkine, M; Harats, D; Hoffman, A; Leitersdorf, E; Liberman, Y; Meiner, V; Shaish, A; Szalat, A | 1 |
| Gonzalez, FJ | 1 |
| Anthony, MN; Dinchuk, JE; Dulac, HA; Grace, JE; Kim, S; Mosure, KW; Orcutt, T; Pizzano, J; Sauer, MB; Simmermacher, J; Sinz, M; Vuppugalla, R; Zoeckler, ME | 1 |
| Maren, K; Rojkjaer, L; Skerjanec, A; Wang, J | 1 |
| Darnell, M; Edebert, I; Ek, M; Ingelman-Sundberg, M; Neve, EP; Sivertsson, L | 1 |
| Cai, X; Chu, X; Ding, Y; Evers, R; Gibson, C; Reitman, ML; Roupe, K; Stoch, A; Stone, JA; Venkatasubramanian, R; Wagner, JA; Witter, R; Yabut, J; Zajic, S | 1 |
| Collier, AC; Kharasch, ED; Kirby, BJ; Thummel, KE; Unadkat, JD; Whittington, D | 1 |
| Hayashi, M; Shou, M; Skiles, GL; Xu, Y; Zhou, Y | 1 |
| Blood, J; Francis, A; Frey, K; Kharasch, ED; Kim, T; London, A | 1 |
| Bliven-Sizemore, EE; Burman, WJ; Dooley, KE; Dorman, SE; Fuchs, EJ; Hubbard, WC; Lu, Y; Melia, MT; Nuermberger, EL; Weiner, M | 1 |
| Abe, K; Hirouchi, M; Imaoka, T; Izumi, T; Mikkaichi, T; Okudaira, N | 1 |
| Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y | 2 |
| Barter, Z; Jamei, M; Neuhoff, S; Rostami-Hodjegan, A; Turner, DB; Yeo, KR | 1 |
| Alley, SC; Chen, R; Cooper, M; Gopal, AK; Goy, A; Grove, LE; Han, TH; Lynch, CM; Matous, JV; O'Connor, OA; Ramchandren, R | 1 |
| Cho, JY; Choi, MH; Jang, IJ; Lim, KS; Shin, KH; Yu, KS | 1 |
| Akamatsu, T; Chida, K; Inui, N; Karayama, M; Namiki, N; Tanaka, S; Uchida, S; Watanabe, H | 1 |
| Dutreix, C; Lorenzo, S; Munarini, F; Roesel, J; Wang, Y | 1 |
| Bertino, JS; Ma, JD; Nafziger, AN | 1 |
| Hee, KH; Lee, LS; Yao, Z | 1 |
| Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N | 1 |
| Feng, H; Gu, Z; Han Hsu, H; Li, K; Shu, P; Wang, Y; Wu, X; Zhang, L; Zhao, S | 1 |
| Boulton, DW; Goodenough, A; Jemal, M; Kasichayanula, S; LaCreta, F; Lee, M; Luo, WL; Rodrigues, AD; Yang, Z | 1 |
| Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H | 1 |
| Jin, F; Moyer, C; Murray, B; Ramanathan, S; Robeson, M; Wilbert, S; Zhou, H | 1 |
| Tamai, I; Watanabe, M; Watanabe, T; Yabuki, M | 1 |
| Ahn, LY; Cho, JY; Choi, MH; Jang, IJ; Lee, J; Moon, JY; Shin, KH; Yu, KS | 1 |
| Bogman, K; Bordogna, W; Cleary, Y; Dall, G; De Petris, L; Guerini, E; Martin-Facklam, M; Morcos, PN; Phipps, A; Viteri, S; Yu, L | 1 |
| Inoue, T; Kusama, T; Mogi, M; Sasaki, E; Shimizu, M; Toda, A; Uehara, S; Uno, Y; Utoh, M; Yamazaki, H | 1 |
| Chen, Y; Dean, B; Fan, P; Hop, CECA; Ismaili, MHA; Mao, J; Wang, J; Wong, S; Wright, M | 1 |
| Chun, DY; Einolf, HJ; Gu, H; He, H; Lin, W; Mangold, JB; Wang, L; Won, CS | 1 |
| den Adel, M; Garcia-Hernandez, A; Groenendaal-van de Meent, D; Katashima, M; Kato, K; Kusawake, T; Ohtsu, Y; Takada, A | 1 |
| Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L | 1 |
| Arakawa, H; Itoh, M; Kojima, H; Koyama, S; Masuda, N; Ogihara, T; Yano, K | 1 |
| Britz, H; Eissing, T; Frechen, S; Hanke, N; Lehr, T; Moj, D; Wendl, T | 1 |
| Arora, S; Christensen, J; Hughes, L; Lu, S; Wang, J; Wang, X; Zhang, ZY | 1 |
| Hasegawa, M; Tahara, H; Watanabe, M | 1 |
| Cho, JY; Jang, IJ; Kim, AH; Kim, B; Lee, J; Lee, S; Yi, S; Yoon, SH; Yu, KS | 1 |
| Hopkins, A; Marshall, JC; Miners, JO; Rowland, A; Sorich, MJ; van Dyk, M; Wood, LS | 1 |
| Kapetas, AJ; Rodrigues, AD; Rowland, A; Sorich, MJ | 1 |
| Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C | 1 |
| Brudny-Klöppel, M; Fricke, R; Friedrich, C; Gashaw, I; Höchel, J; Klein, S; Nowotny, B; Riecke, K; Rottmann, A; Wiesinger, H | 1 |
| Chan, TS; Raymond, K; Scaringella, YS; Taub, ME | 1 |
| Chakraborty, A; Dhuria, SV; Elmeliegy, M; He, H; Heimbach, T; Huth, F; Ji, Y; Miller, M; Samant, TS; Schiller, H; Umehara, K | 1 |
| Chhibber, A; Chu, X; Crumley, T; Evers, R; Gillespie, A; Larson, P; Lasseter, KC; Lassman, M; Latham, AH; Marbury, TC; Marenco, T; Marricco, NC; Mostoller, K; Murphy, M; Pang, J; Paul, E; Stoch, SA; Sutradhar, S; Tatosian, DA; Tweedie, D; Wang, YJ; Wen, J; Yee, KL; Zhang, Z | 1 |
| Battegay, M; Courlet, P; Decosterd, LA; Kinvig, H; Marzolini, C; Penny, MA; Siccardi, M; Stader, F | 1 |
| Chen, Y; Ding, H; Girish, S; Jin, J; Li, C; Lu, D; Ma, F; Mao, J; Miles, D; Samineni, D; Shi, R; Wright, M | 1 |
| Fahmy, A; Johnson, JG; Kapetas, AJ; Mounzer, R; Newman, LA; Rodrigues, AD; Rowland, A; Sorich, MJ; Useckaite, Z; van Dyk, M; Wood, LS | 1 |
| Burke, W; Cantarini, M; Frewer, P; Goldwater, R; Han, D; Hara, I; Li, Y; Ren, S; Scarfe, G; Schalkwijk, S; Vishwanathan, K | 1 |
| Blank, A; Burhenne, J; Elbe, A; Foerster, KI; Haefeli, WE; Mikus, G; Rose, P | 1 |
| Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W | 1 |
| Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L | 1 |
| Burhenne, J; Gottwalt, K; Haefeli, WE; Hohmann, N; Huisinga, W; Kloft, C; Meid, AD; Michelet, R; Mikus, G; Nassar, YM | 1 |
| Chae, JW; Kim, JK; Kim, SK; Song, YM; Tran, QT; Vu, NT; Yun, HY | 1 |
| Barth, A; Brimhall, DB; Dumont, EF; Nguyen, D; Perry, CR; Shabbir, S; Srinivasan, M; Swift, B; Thomas, S; Zamek-Gliszczynski, MJ | 1 |
| Benhadji, KA; Gao, L; He, Y; Hunt, A; Mina, M; Sonnichsen, D; Takenaka, T; Yamamiya, I | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
4 review(s) available for midazolam and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Transporter-mediated drug interactions: clinical implications and in vitro assessment.
Topics: Animals; Area Under Curve; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Membrane Transport Proteins; Midazolam; Pharmaceutical Preparations; Rifampin | 2007 |
CYP3A4 and pregnane X receptor humanized mice.
Topics: Animals; Chromosomes, Artificial, Bacterial; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Estrogens; Forecasting; Humans; Ketoconazole; Male; Mice; Mice, Knockout; Mice, Transgenic; Midazolam; Models, Animal; Pregnane X Receptor; Receptors, Steroid; Rifampin; Sex Factors | 2007 |
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
Topics: Adult; Aged; Aged, 80 and over; Aging; Clarithromycin; Cohort Studies; Comorbidity; Computer Simulation; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Models, Biological; Polypharmacy; Prospective Studies; Rifampin; Young Adult | 2021 |
32 trial(s) available for midazolam and rifampin
| Article | Year |
|---|---|
Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Topics: Administration, Oral; Adult; Analysis of Variance; Antibiotics, Antitubercular; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Enzyme Induction; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Mixed Function Oxygenases; Psychomotor Performance; Reference Values; Rifampin | 1996 |
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Itraconazole; Male; Midazolam; Oxidoreductases, N-Demethylating; Rifampin | 1998 |
Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; GABA Modulators; Humans; Hydrocortisone; Male; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Predictive Value of Tests; Rifampin | 2001 |
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Topics: Adult; Alfentanil; Analgesics, Opioid; Antibiotics, Antitubercular; Area Under Curve; Cross-Over Studies; Female; GABA Modulators; Half-Life; Humans; Liver; Male; Midazolam; Miosis; Pilot Projects; Pupil; Rifampin | 2001 |
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Topics: Administration, Oral; Adult; Aged; Aging; Algorithms; Antibiotics, Antitubercular; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Female; Humans; Hypnotics and Sedatives; Injections, Intravenous; Intestines; Liver; Male; Mass Spectrometry; Midazolam; Oxidoreductases, N-Demethylating; Rifampin; Sex Characteristics | 2003 |
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.
Topics: Adolescent; Adult; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam; Middle Aged; Naltrexone; Oxymorphone; Rifampin; Tolbutamide | 2005 |
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
Topics: Adult; Caffeine; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Expression Regulation, Enzymologic; Humans; Leukocytes, Mononuclear; Male; Midazolam; Omeprazole; Rifampin; RNA, Messenger | 2005 |
Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Area Under Curve; Cimicifuga; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dietary Supplements; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Phenotype; Rifampin; Sex Characteristics; Silybum marianum | 2006 |
Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.
Topics: Adult; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dietary Supplements; Enzyme Induction; Enzyme Inhibitors; Female; Herb-Drug Interactions; Humans; Hydrastis; Kava; Male; Midazolam; Models, Biological; Phenotype; Plant Preparations; Rifampin; Risk Assessment; Substrate Specificity | 2008 |
Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
Topics: Adult; Antibiotics, Antitubercular; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestanol; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Activation; GABA Modulators; Humans; Male; Midazolam; Rifampin; Xanthomatosis, Cerebrotendinous | 2007 |
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.
Topics: Adult; Anesthetics, Intravenous; Aryl Hydrocarbon Hydroxylases; Benzoates; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Deferasirox; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Iron Chelating Agents; Male; Midazolam; Piperidines; Rifampin; Triazoles | 2010 |
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Topics: Administration, Oral; Adolescent; Adult; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Activation; Enzyme Induction; Female; HIV Protease Inhibitors; Humans; Injections, Intravenous; Intestines; Liver; Male; Midazolam; Middle Aged; Nelfinavir; Rifampin; Ritonavir; Substrate Specificity; Tissue Distribution; Young Adult | 2011 |
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
Topics: Adult; Antitubercular Agents; Area Under Curve; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Midazolam; Middle Aged; Rifampin | 2012 |
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Topics: Adult; Biomarkers; Cholesterol; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Humans; Hydrocortisone; Hydroxycholesterols; Male; Metabolic Clearance Rate; Midazolam; Rifampin | 2013 |
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Feces; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Ketoconazole; Ki-1 Antigen; Male; Midazolam; Middle Aged; Oligopeptides; Rifampin; Young Adult | 2013 |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
Topics: Adult; Biomarkers; Cortisone; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Induction; Gas Chromatography-Mass Spectrometry; Humans; Hydrocortisone; Hydroxycholesterols; Ketoconazole; Liver; Male; Metabolomics; Midazolam; Pharmacogenetics; Rifampin; Young Adult | 2013 |
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Topics: Adult; Antineoplastic Agents; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Rifampin; Staurosporine; Tandem Mass Spectrometry; Young Adult | 2013 |
Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Calibration; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Freezing; Glucuronosyltransferase; Healthy Volunteers; Humans; Ketoconazole; Midazolam; Particle Size; Pyrrolidinones; Quality Control; Raltegravir Potassium; Reproducibility of Results; Rifampin; Ritonavir; Solid Phase Extraction; Tandem Mass Spectrometry; Xenobiotics | 2014 |
Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Topics: Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydrocortisone; Hydroxycholesterols; Midazolam; Quinidine; Quinine; Rifampin | 2014 |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Topics: Adolescent; Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydroxycholesterols; Injections, Intravenous; Ketoconazole; Limit of Detection; Midazolam; Middle Aged; Rifampin; Saliva; Substrate Specificity; Time Factors; Tissue Distribution; Young Adult | 2014 |
Clinical drug interaction profile of idelalisib in healthy subjects.
Topics: Adult; Antineoplastic Agents; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Rifampin; Rosuvastatin Calcium; Young Adult | 2015 |
Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Biomarkers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Female; Humans; Hydrocortisone; Ketoconazole; Liver; Metabolic Clearance Rate; Metabolomics; Midazolam; Middle Aged; Rifampin; Young Adult | 2016 |
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Topics: Adult; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Piperidines; Receptor Protein-Tyrosine Kinases; Rifampin; Treatment Outcome; Triazoles; Young Adult | 2017 |
Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Neurokinin-1 Receptor Antagonists; Rifampin; Spiro Compounds | 2019 |
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Midazolam; Rifampin; Young Adult | 2019 |
Identification of the caffeine to trimethyluric acid ratio as a dietary biomarker to characterise variability in cytochrome P450 3A activity.
Topics: Adult; Biomarkers; Caffeine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Diet; Genotype; Humans; Male; Midazolam; Phenotype; Racial Groups; Rifampin; Uric Acid; Young Adult | 2019 |
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Topics: Aged; Cells, Cultured; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Enzyme Induction; Female; Humans; Itraconazole; Male; Membrane Transport Proteins; Microsomes, Liver; Midazolam; Middle Aged; Pyrazoles; Rifampin; Rosuvastatin Calcium | 2019 |
The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
Topics: Aged; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Ethinyl Estradiol; Female; Germany; Humans; Midazolam; Middle Aged; Patient Safety; Progestins; Protein Binding; Rifampin; Risk Assessment; Sex Hormone-Binding Globulin | 2020 |
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Biotransformation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Midazolam; Models, Theoretical; Patient Safety; Purines; Rifampin; Risk Assessment; Ritonavir | 2020 |
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biomarkers; Drug Interactions; Healthy Volunteers; Humans; Kidney Diseases; Liver-Specific Organic Anion Transporter 1; Midazolam; Rifampin | 2021 |
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer.
Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metformin; Midazolam; Prospective Studies; Pyrimidines; Pyrroles; Rifampin; Topotecan | 2022 |
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
Topics: Administration, Oral; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Midazolam; Pharmaceutical Preparations; Rifampin; Voriconazole | 2022 |
57 other study(ies) available for midazolam and rifampin
| Article | Year |
|---|---|
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Blotting, Northern; Cell Line; Clotrimazole; Colonic Neoplasms; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme System; Dexamethasone; DNA Primers; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Midazolam; Mixed Function Oxygenases; Molecular Sequence Data; Multigene Family; Phenobarbital; Phenytoin; Polymerase Chain Reaction; Rifampin; Tumor Cells, Cultured; Verapamil | 1996 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver.
Topics: Animals; Cyclosporins; Cytochrome P-450 Enzyme System; Enzyme Induction; Erythromycin; In Vitro Techniques; Isoenzymes; Male; Microsomes, Liver; Midazolam; Rabbits; Rifampin; Troleandomycin | 1988 |
Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Evaluation Studies as Topic; Humans; Midazolam; Oxidoreductases, N-Demethylating; Rifampin; Sensitivity and Specificity | 1998 |
Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Cryopreservation; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diazepam; Dose-Response Relationship, Drug; Enzyme Induction; Glucuronosyltransferase; Humans; Liver; Midazolam; Organ Preservation; Oxazines; Oxidoreductases, N-Demethylating; Rifabutin; Rifampin; Testosterone; Zidovudine | 1999 |
Induction of the metabolism of midazolam by rifampin in cultured porcine hepatocytes: preliminary evidence for CYP3A isoforms in pigs.
Topics: Animals; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Enzyme Induction; Humans; Isoenzymes; Liver; Midazolam; Oxidoreductases, N-Demethylating; Rats; Rifampin; RNA, Messenger; Substrate Specificity; Swine | 1999 |
Evaluation of the effect of culture matrices on induction of CYP3A isoforms in cultured porcine hepatocytes.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Cell Culture Techniques; Cell Size; Cells, Cultured; Collagen; Culture Media; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Immunoblotting; Isoenzymes; Liver; Male; Microsomes, Liver; Midazolam; Oxidoreductases, N-Demethylating; Rifampin; Swine | 2000 |
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
Topics: Amiodarone; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Chromatography, High Pressure Liquid; Cimetidine; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ketoconazole; Kinetics; Microsomes, Liver; Midazolam; Models, Chemical; Oxidoreductases, N-Demethylating; Protein Isoforms; Quinidine; Rabbits; Rifampin; Time Factors | 2001 |
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blotting, Southern; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; In Vitro Techniques; Intestine, Small; Ketoconazole; Male; Mice; Mice, Transgenic; Microsomes; Midazolam; Polymerase Chain Reaction; Rifampin; Time Factors | 2003 |
Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Area Under Curve; Black or African American; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Erythromycin; Exons; Female; Genetic Variation; Genotype; Homozygote; Humans; Intestinal Mucosa; Liver; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Phenotype; Polymorphism, Genetic; Rifampin; White People | 2003 |
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.
Topics: Adult; Asian People; Biological Availability; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genetic Variation; Genotype; Humans; Infusions, Intravenous; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Rifampin; Sensitivity and Specificity | 2004 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Topics: Adolescent; Adult; Aged; Animals; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Ethers; Female; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hydroxylation; Infusions, Intravenous; Isoenzymes; Macaca mulatta; Male; Midazolam; Middle Aged; Models, Animal; Recombinant Proteins; Rifampin; RNA, Messenger | 2006 |
Rifaximin is a gut-specific human pregnane X receptor activator.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Gastrointestinal Agents; Humans; Intestinal Mucosa; Intestines; Male; Mice; Midazolam; Pregnane X Receptor; Receptors, Steroid; Rifampin; Rifamycins; Rifaximin | 2007 |
Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Topics: Adult; Amino Acid Sequence; Animals; Bridged Bicyclo Compounds; Cell Line; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Gene Expression; Hepatocytes; Humans; Hypericum; Macaca fascicularis; Macaca mulatta; Male; Midazolam; Middle Aged; Models, Animal; Molecular Sequence Data; Phloroglucinol; Plant Extracts; Pregnane X Receptor; Receptors, Steroid; Rifampin; Sequence Homology, Amino Acid; Terpenes; Transcriptional Activation; Transfection; Xenobiotics | 2010 |
CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells.
Topics: Aflatoxin B1; Catalysis; Cell Line; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Gene Expression; Humans; Ketoconazole; Microsomes, Liver; Midazolam; Rifampin; Testosterone; Transcription Factors | 2010 |
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Digoxin; Drug Interactions; Humans; Male; Midazolam; Middle Aged; Models, Biological; Organic Anion Transporters, Sodium-Independent; Research Design; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2011 |
Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Topics: Area Under Curve; Carbamazepine; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Midazolam; Nifedipine; Phenobarbital; Rifampin; Simvastatin; Substrate Specificity | 2011 |
Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Topics: Administration, Oral; Adolescent; Adult; Alfentanil; Analgesics, Opioid; Area Under Curve; Biological Availability; Cross-Over Studies; Cytochrome P-450 CYP3A; Enzyme Induction; Female; Half-Life; Humans; Hypnotics and Sedatives; Injections, Intravenous; Kinetics; Leprostatic Agents; Liver; Male; Midazolam; Miosis; Rifampin; Smoking; Young Adult | 2011 |
Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor.
Topics: Animals; Drug Interactions; Female; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Metabolic Clearance Rate; Midazolam; Organic Anion Transporters; Rats; Rats, Sprague-Dawley; Rifampin; Sulfobromophthalein | 2013 |
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Topics: Adjuvants, Anesthesia; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B; Computer Simulation; Digoxin; Drug Interactions; Enzyme Inhibitors; Humans; Midazolam; Models, Biological; Permeability; Rifampin; Verapamil | 2013 |
Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Topics: Adult; Antibiotics, Antitubercular; Asian People; Caffeine; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Imidazoles; Losartan; Male; Midazolam; Omeprazole; Rifampin; Tetrazoles; Theophylline; Time Factors; Withholding Treatment | 2013 |
Endogenous 4β-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity.
Topics: Cytochrome P-450 CYP3A; Female; Humans; Hydroxycholesterols; Male; Midazolam; Rifampin | 2013 |
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Topics: Alfentanil; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Hepatocytes; Humans; Midazolam; Models, Biological; Nifedipine; Rifampin; Tissue Distribution; Triazolam | 2014 |
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Topics: Administration, Oral; Animals; Biomarkers; Biotransformation; Cholesterol; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Drug Evaluation, Preclinical; Enzyme Induction; Female; Hydroxycholesterols; Macaca fascicularis; Male; Midazolam; Rifampin; Substrate Specificity; Tandem Mass Spectrometry | 2014 |
Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Topics: Brentuximab Vedotin; Computer Simulation; Drug Interactions; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin | 2015 |
Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.
Topics: Administration, Oral; Animals; Dehydroepiandrosterone Sulfate; Drug Interactions; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macaca fascicularis; Male; Midazolam; Organic Anion Transporters; Rifampin; Temperature | 2015 |
Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
Topics: Administration, Intravenous; Aging; Animals; Caffeine; Callithrix; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Metoprolol; Midazolam; Omeprazole; Rifampin; Substrate Specificity; Warfarin | 2018 |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
Topics: Administration, Oral; Animals; Computer Simulation; Cytochrome P-450 CYP3A; Drug Discovery; Drug Interactions; Enzyme Induction; Humans; Hydrocortisone; Hydroxycholesterols; Liver; Macaca fascicularis; Midazolam; Models, Biological; Pharmacokinetics; Rifampin; RNA, Messenger | 2017 |
Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Induction; Gastric Acidity Determination; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Microsomes, Liver; Midazolam; Models, Biological; Oxidation-Reduction; Panobinostat; Rifampin | 2017 |
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Interactions; Enzyme Induction; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Oxadiazoles; Rifampin; Warfarin; Young Adult | 2017 |
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Ketoconazole; Male; Midazolam; Middle Aged; Models, Biological; Rifampin; Staurosporine; Young Adult | 2018 |
Evaluation of the metabolic capability of primary human hepatocytes in three-dimensional cultures on microstructural plates.
Topics: Acetaminophen; Adenosine Triphosphate; Arylsulfotransferase; Cell Culture Techniques; Cells, Cultured; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme System; Diclofenac; Glucuronosyltransferase; Hepatocytes; Humans; Lamotrigine; Midazolam; Omeprazole; Rifampin; RNA, Messenger; Triazines | 2018 |
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Topics: Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological; Rifampin | 2018 |
A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Topics: Alprazolam; Animals; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Hydrocortisone; Hydroxycholesterols; Macaca fascicularis; Male; Midazolam; Rifampin; Triazolam | 2019 |
Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Intestines; Liver; Male; Midazolam; Models, Biological; Rifampin; Sex Factors; Time Factors; Young Adult | 2019 |
Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture.
Topics: Adult; Alprazolam; Cells, Cultured; Coculture Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Erythromycin; Female; Glucuronosyltransferase; Hepatobiliary Elimination; Hepatocytes; Humans; Male; Midazolam; Middle Aged; Primary Cell Culture; Rifampin; Time Factors | 2020 |
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Topics: Antibodies, Monoclonal; Brentuximab Vedotin; Computer Simulation; Cytochrome P-450 CYP3A; Drug Development; Drug Interactions; Drug Labeling; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin | 2020 |
Exploring the Use of Serum-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Hepatic Cytochromes P450 and Organic Anion Transporting Polypeptides.
Topics: Adult; Area Under Curve; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Induction; Extracellular Vesicles; Female; Genotype; Humans; Liquid Biopsy; Liver; Male; Midazolam; Organic Anion Transporters; Pregnancy; Proteomics; Rifampin; Young Adult | 2021 |
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam.
Topics: Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Famotidine; Humans; Itraconazole; Male; Midazolam; Pyrazines; Rifampin; Triazines | 2022 |
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Fluconazole; Humans; Midazolam; Omeprazole; Rifampin; Sodium Bicarbonate; Yohimbine | 2022 |
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide | 2022 |
Beyond the Michaelis-Menten: Accurate Prediction of Drug Interactions Through Cytochrome P450 3A4 Induction.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Midazolam; Pharmaceutical Preparations; Rifampin | 2023 |
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
Topics: Cimetidine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Membrane Transport Proteins; Midazolam; Models, Biological; Pharmaceutical Preparations; Rifampin | 2023 |
Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Humans; Itraconazole; Midazolam; Rifampin | 2023 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |